Simcere has reported the SMARCA2 degrader ZM‐0011 (SCR‐9140), which significantly reduces intra‐tumoural SMARCA2 levels and suppresses tumour growth in mouse models, with a favourable tolerability profile.227. This evidence concerns the gene SMARCA2 and neoplasm.